In a welcome move, Danaher saw its Relative Strength Rating improve from 68 to 75 on Monday.
IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the best stocks tend to have an RS Rating of at least 80 in the early stages of their moves. See if Danaher can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
Danaher is not currently near a potential buy zone. See if the stock goes on to form a promising consolidation that could spark a new run.
Although earnings and sales growth came in at -6% and -3%, respectively, in the latest report, that showed improvement for both the top and bottom lines. The company is expected to release its next quarterly numbers on or around Jul. 18.
The company earns the No. 4 rank among its peers in the Medical-Diversified industry group. AstraZeneca ADR is the No. 1-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
